PharmaShots | Incisive News in 3 Shots

Subscribe Now

Dupixent

Top 20 Biopharma Companies of 2025

Top 20 Biopharma Companies of 2025

April 24, 2025

Regeneron and Sanofi Report the US FDA’s Approval of Dupixent for Chronic Spontaneous Urticaria

Regeneron and Sanofi Report the US FDA’s Approval of Dupixent for Chronic Spontaneous Urticaria

April 21, 2025

Sanofi and Regeneron’s Dupixent Receives the MHLW’s Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

Sanofi and Regeneron’s Dupixent Receives the MHLW’s Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

March 28, 2025

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance for Dupixent to Treat Bullous Pemphigoid (BP)

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance for Dupixent to Treat Bullous Pemphigoid (BP)

February 18, 2025

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance of Dupixent (Dupilumab) to Treat Chronic Spontaneous Urticaria (CSU)

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance of Dupixent (Dupilumab) to Treat Chronic Spontaneous Urticaria (CSU)

November 15, 2024

Sanofi and Regeneron Reports the EC’s Approval of Dupixent (Dupilumab) for Young Children with Eosinophilic Esophagitis (EoE)

Sanofi and Regeneron Reports the EC’s Approval of Dupixent (Dupilumab) for Young Children with Eosinophilic Esophagitis (EoE)

November 6, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us